News
Company News: Mikrogen erhält CE-Zertifizierung für Antikörpertest zum Nachweis von SARS-CoV-2 / COVID-19
– German only –
— Test kompatibel mit üblichen Laborautomaten (ELISA-Systemen)
— Herstellung von 1.600.000 Testkits pro Monat möglich
— Lösung erlaubt erstmals zuverlässige, kostengünstige und flächendeckende Testung
Mikrogen GmbH, ein Unternehmen, das gentechnisch hergestellte in vitro Diagnostika entwickelt, hat heute die CE-Kennzeichnung seines recomWell SARS-CoV-2 IgG-Tests bekannt gegeben.
Company News: TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection
– Product shows excellent safety and tolerability
– Enables long-term reduction of standard medications and side effects while maintaining immune tolerance and transplant function
– Findings endorsed by third-party experts
TolerogenixX GmbH, a biopharmaceutical company developing personalized, cellular therapies to combat organ rejection and autoimmune diseases, today announced the publication of positive Phase Ib results of its lead product MIC-Lx in The Journal of Clinical Investigation (https://doi.org/10.1172/JCI133595). Read more…
Company News: BellaSeno Appoints Dr. Mohit Chhaya as Chief Executive Officer
– Former CEO Dr. Simon Champ to become a member of BellaSeno´s Supervisory Board
BellaSeno GmbH, an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced that co-founder and former Chief Technology Officer Dr. Mohit Chhaya, PhD, has been appointed as the Company´s Chief Executive Officer. Starting on April 1, 2020, he will take over duties from BellaSeno´s current CEO and co-founder Dr. Simon Champ, MBA. Simon Champ will become a member of BellaSeno’s Supervisory Board.
Company News: BellaSeno and Charité – Universitätsmedizin Berlin Collaborate Under BMBF-Funded SyMBoD Consortium
— Development of absorbable implants for the personalized treatment of bone defects in patients with diabetes
— BellaSeno responsible for high resolution, medical-grade scaffold manufacturing under ISO 13485
BellaSeno GmbH, a company developing absorbable scaffolds using additive manufacturing technologies, today announced a collaboration with Charité – Universitätsmedizin Berlin under the recently established SyMBoD consortium.